Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006113 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00006113 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 25 participants.
The verdict
NCT00006113, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying giving vaccine therapy together with interferon gamma and interleukin-2 in treating patients with stage III or stage IV melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon gamma
- BIOLOGICAL gp100 antigen
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL recombinant CD40-ligand
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-06 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006113
The ClinicalTrials.gov registry entry for NCT00006113 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which aldesleukin is the first listed.
NCT00006113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006113 about?
NCT00006113 is a clinical study titled "Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological...
What is the current status of trial NCT00006113?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1999-06. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00006113?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL), gp100 antigen (BIOLOGICAL), MART-1 antigen (BIOLOGICAL), recombinant CD40-ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006113?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.